Category - Developments

Developments

Soricimed to present four posters at AACR

Closely-held Soricimed Biopharma and collaborators plan to present four posters at the American Association of Cancer Research (AACR) annual meeting in New Orleans on April 16-20. The presentations are based on...

April 13, 2016

Developments

USPTO extends Oramed patent term

The U.S. Patent and Trademark Office has issued a patent term adjustment (PTA) extending the patent term by 18 months for Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent titled, “Methods and Compositions for Oral...

April 13, 2016

Developments

Can-Fite reports preclinical data in erectile dysfunction

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its drug candidate, CF602, showing statistically significant full recovery from erectile dysfunction after one single dose treatment in a...

April 12, 2016

Developments

Profound Medical receives CE Mark to sell Tulsa-Pro

Profound Medical (TSX-V:PRN) has received CE Mark approval for the commercial sale of Tulsa-Pro. Profound’s novel technology combines real-time magnetic resonance imaging with transurethral robotically-driven ultrasound...

April 12, 2016

Developments

Oramed completes Phase 2b oral insulin study

Oramed Pharmaceuticals (NASDAQ:ORMP) said that all follow-up visits in its Phase 2b study of its oral insulin capsule, ORMD-0801, have been completed. The double-blind, randomized Phase 2b study of 180 patients with...

April 6, 2016

Developments

Piper resumes coverage of NxStage Medical at overweight

Piper Jaffray has resumed coverage of NxStage Medical (NASDAQ:NXTM) with an “overweight” rating and $18.50 price target, down from $23 previously. The stock closed at $14.96 on Wednesday. “We have known the story since...

March 31, 2016

Developments

Oramed gets Indian patent for oral administration of proteins

Oramed Pharmaceuticals’ (NASDAQ:ORMP) patent for its invention, titled “Methods and Compositions for Oral Administrations of Proteins” has been granted by the Indian Patent Office. Oramed is seeking to revolutionize the...

March 29, 2016

Developments

HHS ups buprenorphine prescribing to treat opioid addiction

In a speech today, President Obama announced that the Department of Health and Human Services (HHS) has issued a new proposed rule to increase the current patient limit for qualified physicians who prescribe...

March 29, 2016

Developments

Dipexium Pharma receives Locilex patent in Japan

Dipexium Pharmaceuticals (NASDAQ:DPRX) has received a patent in Japan, covering a novel formulation of Locilex, an antimicrobial peptide formulated as a topical cream. The issued patent has an expiry date in June 2033...

March 28, 2016

Developments

TransEnterix updates SurgiBot FDA submission

TransEnterix (NYSE MKT:TRXC) has received an update from the FDA on the status of the 510(k) submission for its robotics SurgiBot system to improve minimally invasive surgery. The FDA advised the company that it has not...

March 27, 2016

Category - Developments

Soricimed to present four posters at AACR

USPTO extends Oramed patent term

Can-Fite reports preclinical data in erectile dysfunction

Profound Medical receives CE Mark to sell Tulsa-Pro

Oramed completes Phase 2b oral insulin study

Piper resumes coverage of NxStage Medical at overweight

Oramed gets Indian patent for oral administration of proteins

HHS ups buprenorphine prescribing to treat opioid addiction

Dipexium Pharma receives Locilex patent in Japan

TransEnterix updates SurgiBot FDA submission

General

More